Unlike the more common Zaire ebolavirus—for which the licensed Ervebo vaccine exists—this outbreak is caused by the Bundibugyo virus (BDBV), a rare species of ebolavirus first identified in Uganda in 2007 . There is no approved vaccine or specific treatment for this strain, relying the response heavily on supportive care, early detection, and rigorous contact tracing . Genomic analysis of samples from 22 patients in the DRC and Uganda, published in Nature Medicine on August 11, has confirmed that the 2026 outbreak strain is a new, genetically distinct variant—separate from the Bundibugyo viruses seen in 2007 and 2012—suggesting a fresh animal-to-human spillover event rather than a re-emergence of a previously hidden outbreak .
The outbreak was officially declared on May 15, 2026, but genomic and epidemiological evidence indicates the virus was circulating undetected since at least early January 2026, likely beginning with a woman's death . The epicenter is in the eastern provinces of Ituri, North Kivu, and South Kivu, with spread to Haut-Uele and Tshopo provinces . Uganda recorded two imported cases in Kampala by late May ; overall, Uganda confirmed about 20 cases total, but contained its spread more effectively through swift cross-border surveillance and contact tracing, closing its outbreak on July 28, 2026 .
On August 4, 2026, the WHO announced that testing of experimental treatments, preventive medicines, and vaccines for the Bundibugyo strain was "advancing rapidly" . A WHO-sponsored treatment trial is now operating at three clinical management facilities in Ituri province . A new Phase 1 vaccine trial, the first ever for the Bundibugyo species, began in the UK on July 24, with a second starting in Canada . On August 7, 2026, WHO vaccine experts recommended a full-scale human trial of the existing Ervebo vaccine to test whether it offers cross-protection against the Bundibugyo strain, based on early animal data . Results from these trials are expected to be months away .
Contact tracing remains a critical weakness. Rates improved from roughly 25% to 45% by early June, but remain far below the 90–95% coverage needed to interrupt transmission . As of August 5, contact tracing coverage was reported at 78.4%, still well below the operational target of 95% . The WHO's August 13 update noted that hidden chains of transmission are being fueled by patients who reach advanced stages without care, with deaths still occurring outside health facilities and treatment centers overwhelmed . Major obstacles include armed conflict, mass displacement, community mistrust, and acute hunger in eastern DRC, creating what WHO chief Tedros described as a "catastrophic collision of disease and conflict" .
The WHO is scaling up surveillance, lab diagnostics, contact tracing, clinical care, supply deliveries, and cross-border preparedness . On August 6, WHO and Africa CDC jointly called for urgent community-led action to scale up early detection and contact follow-up . A six-month joint continental plan aims to mobilize $518 million under a "One Response" approach . The outbreak has also drawn global attention, with reports from news agencies like Reuters and Al Jazeera covering the rising toll and the unprecedented medical response gap stemming from the lack of a licensed vaccine for this specific Ebola species.
Unlike the more common Zaire ebolavirus—for which the licensed Ervebo vaccine exists—this outbreak is caused by the Bundibugyo virus (BDBV), a rare species of ebolavirus first identified in Uganda in 2007 . There is no approved vaccine or specific treatment for this strain, relying the response heavily on supportive care, early detection, and rigorous contact tracing . Genomic analysis of samples from 22 patients in the DRC and Uganda, published in Nature Medicine on August 11, has confirmed that the 2026 outbreak strain is a new, genetically distinct variant—separate from the Bundibugyo viruses seen in 2007 and 2012—suggesting a fresh animal-to-human spillover event rather than a re-emergence of a previously hidden outbreak .
The outbreak was officially declared on May 15, 2026, but genomic and epidemiological evidence indicates the virus was circulating undetected since at least early January 2026, likely beginning with a woman's death . The epicenter is in the eastern provinces of Ituri, North Kivu, and South Kivu, with spread to Haut-Uele and Tshopo provinces . Uganda recorded two imported cases in Kampala by late May ; overall, Uganda confirmed about 20 cases total, but contained its spread more effectively through swift cross-border surveillance and contact tracing, closing its outbreak on July 28, 2026 .
On August 4, 2026, the WHO announced that testing of experimental treatments, preventive medicines, and vaccines for the Bundibugyo strain was "advancing rapidly" . A WHO-sponsored treatment trial is now operating at three clinical management facilities in Ituri province . A new Phase 1 vaccine trial, the first ever for the Bundibugyo species, began in the UK on July 24, with a second starting in Canada . On August 7, 2026, WHO vaccine experts recommended a full-scale human trial of the existing Ervebo vaccine to test whether it offers cross-protection against the Bundibugyo strain, based on early animal data . Results from these trials are expected to be months away .
Contact tracing remains a critical weakness. Rates improved from roughly 25% to 45% by early June, but remain far below the 90–95% coverage needed to interrupt transmission . As of August 5, contact tracing coverage was reported at 78.4%, still well below the operational target of 95% . The WHO's August 13 update noted that hidden chains of transmission are being fueled by patients who reach advanced stages without care, with deaths still occurring outside health facilities and treatment centers overwhelmed . Major obstacles include armed conflict, mass displacement, community mistrust, and acute hunger in eastern DRC, creating what WHO chief Tedros described as a "catastrophic collision of disease and conflict" .
The WHO is scaling up surveillance, lab diagnostics, contact tracing, clinical care, supply deliveries, and cross-border preparedness . On August 6, WHO and Africa CDC jointly called for urgent community-led action to scale up early detection and contact follow-up . A six-month joint continental plan aims to mobilize $518 million under a "One Response" approach . The outbreak has also drawn global attention, with reports from news agencies like Reuters and Al Jazeera covering the rising toll and the unprecedented medical response gap stemming from the lack of a licensed vaccine for this specific Ebola species.